DAEWON PHARMACEUTICAL CO.,LTD
Financials
Valuation Metrics
DAEWON PHARMACEUTICAL CO.,LTD's Market Cap is ₩1725B. At end of 2025 it was ₩2680B. Ranked #904 of 2,436 in KR market (top 37%), #479 of 787 on KOSPI (top 61%), #101 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 43%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 172.47B KRW | KR#904/2,436 Sec#101/234 |
| Revenue | 605.66B KRW | KR#545/2,436 Sec#24/234 |
| Net Income | -6.99B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 595.99B KRW | KR#662/2,436 Sec#37/234 |
| Net Assets | 270.98B KRW | KR#744/2,436 Sec#50/234 |
| Employees | 1,332 | KR#195/2,436 Sec#11/234 |
| Value | ||
| P/B | 0.64x | KR#1,053/2,436 Sec#51/234 |
| P/S | 0.28x | KR#565/2,436 Sec#11/234 |
| FCF Yield | 7.25% | KR#739/2,436 Sec#37/234 |
| Profitability | ||
| ROE | -2.58% | KR#1,652/2,436 Sec#118/234 |
| ROA | -1.17% | KR#1,618/2,436 Sec#113/234 |
| Op. Margin | -0.25% | KR#1,613/2,436 Sec#115/234 |
| Revenue Growth | 0.14% | KR#1,428/2,436 Sec#137/234 |
| Earnings Growth | -60.81% | KR#1,251/2,436 Sec#80/234 |
| Financial Health | ||
| Debt Ratio | 219.94% | KR#1,836/2,436 Sec#199/234 |
| Total Debt | 361.11B KRW | KR#354/2,436 Sec#15/234 |
| FCF | 12.51B KRW | KR#652/2,436 Sec#38/234 |
| Cash | 27.95B KRW | KR#1,047/2,436 Sec#70/234 |
| Current Ratio | 1.18x | KR#1,597/2,436 Sec#166/234 |
| Dividend | ||
| Div. Yield | 3.34% | KR#586/2,436 Sec#25/234 |
| Div. Growth | -16.67% | KR—/2,436 Sec—/234 |
| Performance | ||
| 1Y Return | -41.16% | KR#1,863/2,436 Sec#166/234 |
| 1M Return | -4.35% | KR#1,336/2,436 Sec#136/234 |
| From 52W High | -43.75% | KR#923/2,436 Sec#68/234 |
| 1Y MDD | -46.32% | KR#757/2,436 Sec#64/234 |
| Trading | ||
| Volume | 26,764 shares | KR#1,722/2,436 Sec#175/234 |
| Foreign Own. | 13.60% | KR#357/2,436 Sec#26/234 |
| Per Share | ||
| EPS | -195 KRW | KR—/2,436 Sec—/234 |
| BPS | 12,263 KRW | KR#806/2,436 Sec#57/234 |
Company Info
Daewon Pharmaceutical, incorporated in 1961, currently holds 11 subsidiaries, with Beijing Skinlala's liquidation expected by 2025. The company's core business involves manufacturing and selling pharmaceuticals, cosmetics, and health functional foods, supplying new drugs, incrementally modified drugs, and generic drugs to domestic medical institutions. Leveraging excellent GMP-certified production facilities and specialized products, Daewon Pharmaceutical engages in CMO business, exports finished pharmaceuticals and medical devices, and operates a health functional food business focused on Jangdaewon. The company is headquartered in Seongdong-gu, Seoul.